Every 10-Q that eXoZymes Inc (EXOZ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EXOZ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EXOZ filings page.
eXoZymes Inc., a pre-revenue synthetic biology company, reported a larger net loss of $5.25M for the six months ended June 30, 2026, compared with $4.22M a year earlier, driven mainly by an 85.7% increase in R&D spending to $2.56M. General and administrative costs declined 10.9% to $2.78M.
Cash and cash equivalents rose to $5.65M from $3.04M at year-end 2025, primarily from June 2026 equity offerings that generated $5.86M in net proceeds and added 732,260 shares and 366,130 warrants. Working capital reached $4.55M, but the company remains pre-revenue and used $3.16M in operating cash over six months.
Management disclosed substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses and funding needs despite near-term liquidity. A new warrant liability of $1.90M was recorded for investor warrants, and the company continues to rely on government research grants and future financings. Management also identified material weaknesses in internal control over financial reporting.
eXoZymes Inc. reported another pre-revenue quarter for the three months ended March 31, 2026, with a net loss of $2.37 million, wider than the $1.86 million loss a year earlier. Higher research and development spending, which nearly doubled to $1.12 million, and increased compensation costs drove the larger loss.
Cash and cash equivalents fell to $1.44 million after operating cash outflows of $1.52 million, leaving working capital of about $0.51 million. Management states there is substantial doubt about the company’s ability to continue as a going concern without new funding and is pursuing grants and a proposed public equity offering of approximately $15 million under an existing $50 million shelf registration.
eXoZymes Inc. (EXOZ) filed its Q3 2025 10-Q, reporting continued operating losses and a going concern warning. The company posted a net loss of $2,286,991 for the quarter and $6,503,698 for the nine-month period. Basic and diluted EPS were $(0.27) for the quarter and $(0.78) year-to-date.
Cash and cash equivalents were $5,098,687 as of September 30, 2025, down from $9,719,310 at year-end, reflecting operating cash outflows of $4,528,240 for the nine months. Operating costs rose to $7,020,981 year-to-date, driven by higher general and administrative expenses of $4,426,216 and research and development costs, net of grants, of $2,594,765. Grants offset R&D by $1,120,907 year-to-date, including $256,474 in Q3.
The company recorded a discrete income tax receivable of $105,826 in Q3. Management states there is substantial doubt about the company’s ability to continue as a going concern given its pre-revenue status and anticipated funding shortfalls. Shares outstanding were 8,387,250 as of November 13, 2025.